A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received Pfizer Inc's (NYSE: PFE) COVID-19 vaccine, Moderna Inc (NASDAQ: MRNA) vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations.

• Lower risk was observed across all age groups, comorbidity-burden categories, and race.

• Authors of the study, published as a pre-print last week, noted differences between Moderna's mRNA-1273 vaccine and Pfizer's BNT162b2 "in risk of infection or hospitalization were progressively greater when the follow-up period was longer."

• Related: Pfizer's Omicron-Targeted Vaccine Expected To Be Ready In March: CEO Says On CNBC.

• The study evaluated over 900,000 vaccine recipients, followed for a mean of 192 days, during which there were almost 17,000 infections, more than 3,500 hospitalizations, and 381 deaths.

• While fewer patients who received Moderna's vaccine died than Pfizer (168 versus 213), the researchers said this difference was not statistically significant.

• Price Action: PFE stock is up 0.17% at $56.32, MRNA stock is down 4.63% at $222.88 during the market session on the last check Tuesday.

See more from Benzinga

• Pfizer's Omicron-Targeted Vaccine Expected To Be Ready In March: CEO Says On CNBC

• Moderna At Annual J.P. Morgan Healthcare Conference, Inks Oncology Pact With Carisma Therapeutics

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.